ALX Oncology Holdings Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

ALX Oncology Holdings hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

-82.2%

Rückkaufsrendite

Gesamte Aktionärsrendite	-82.2%
Zukünftige Dividendenrendite	0%
Wachstum der Dividende	n/a
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Ausschüttungsquote	n/a

Jüngste Updates zu Dividenden und Rückkäufen

Keine Aktualisierungen

Recent updates

ALX Oncology stock rises on FDA fast track status for evorpacept to treat head/neck cancer

Aug 01

ALX Oncology stock rises 14% on evorpacept's FDA orphan drug status for blood cancer

Jun 29

ALX Oncology Is Turning Into An Also-Ran In Anti-CD47

Feb 15

ALX Oncology Stock: Attractive After Recent Data And Slump In Price

Nov 30

ALX Oncology Is The Next CD47 Biotech To Watch After Recent Acquisitions In This Space

Sep 08

Here's Why We're Not Too Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Situation

Jul 08

Dosing underway in ALX Oncology's ALX148 combo study in head and neck cancer

May 10

We're Not Very Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Rate

Mar 25

Here's What ALX Oncology Holdings Inc.'s (NASDAQ:ALXO) Shareholder Ownership Structure Looks Like

Feb 01

ALX Oncology: All Their Eggs In The Proverbial Basket

Jan 07

ALX Oncology (ALXO) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow

Dec 11

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von ALXO in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von ALXO gestiegen sind.

Dividendenrendite im Vergleich zum Markt

ALX Oncology Holdings Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von ALXO im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (ALXO)	n/a
Untere 25 % des Marktes (US)	1.4%
Markt Top 25 % (US)	4.2%
Branchendurchschnitt (Biotechs)	2.3%
Analystenprognose (ALXO) (bis zu 3 Jahre)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von ALXO im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von ALXO im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von ALXO, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da ALXO keine Ausschüttungen gemeldet hat.

ALX Oncology Holdings Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Updates zu Dividenden und Rückkäufen

Recent updates

New major risk - Revenue and earnings growth

ALX Oncology Holdings Inc. Appoints Alan Sandler as Chief Medical Officer

ALX Oncology Holdings Inc. Announces Resignation of Sophia Randolph as Chief Medical Officer, Effective October 11, 2024

New minor risk - Market cap size

ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations

ALX Oncology Holdings Inc. Announces First Patients Dosed with Evorpacept and Sarclisa as Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi

Price target decreased by 30% to US$9.27

ALX Oncology Holdings Inc. Announces Board Changes

Price target decreased by 7.9% to US$19.33

New major risk - Share price stability

ALX Oncology Holdings Inc. Reports Topline Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients with HER2-Positive Gastric Cancer

Founder notifies of intention to sell stock

Founder recently sold US$63k worth of stock

ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation

Chief Financial Officer recently bought US$102k worth of stock

Founder notifies of intention to sell stock

ALX Oncology Holdings Inc. Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 Aspen-07 Clinical Trial in Patients with Advanced Bladder Cancer

New major risk - Revenue and earnings growth

Founder notifies of intention to sell stock

ALX Oncology Appoints Allison Dillon as Chief Business Officer

ALX Oncology Holdings Inc. Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer

Less than half of directors are independent

ALX Oncology Holdings Inc., Annual General Meeting, Jun 12, 2024

Founder notifies of intention to sell stock

ALX Oncology: Trying To Justify The Hype

ALX Oncology Holdings Inc. Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)

Founder notifies of intention to sell stock

Is ALX Oncology Holdings (NASDAQ:ALXO) Using Debt In A Risky Way?

Price target increased by 17% to US$20.07

Founder recently sold US$108k worth of stock

ALX Oncology Holdings Inc. has completed a Follow-on Equity Offering in the amount of $54.998752 million.

ALX Oncology Holdings Inc. has completed a Follow-on Equity Offering in the amount of $54.998752 million.

New minor risk - Shareholder dilution

ALX Oncology Holdings Inc. Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

ALX Oncology Holdings Inc. Appoints Jason Lettmann as Chief Executive Officer

New major risk - Revenue and earnings growth

ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer

Chief Medical Officer & Director exercised options to buy US$479k worth of stock.

Alx Oncology Announces Initial Data from Aspen-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia

Alx Oncology Announces Initial Data from Aspen-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia

ALX Oncology Holdings Inc. Appoints Scott Garland to Its Board of Directors

Price target decreased to US$35.00

High number of new and inexperienced directors

Price target decreased to US$35.00

Price target decreased to US$38.88

ALX Oncology Holdings Inc. Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer

Price target decreased to US$38.88

ALX Oncology GAAP EPS of -$0.81 misses by $0.18

ALX Oncology's Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma

ALX Oncology stock rises on FDA fast track status for evorpacept to treat head/neck cancer

ALX Oncology stock rises 14% on evorpacept's FDA orphan drug status for blood cancer

ALX Oncology Holdings Inc.(NasdaqGS:ALXO) dropped from Russell 2000 Growth Index

Price target decreased to US$43.25

ALX Oncology Holdings Inc Announces Evorpacept Clinical Program Updates

Price target decreased to US$45.63

Price target decreased to US$49.38

High number of new and inexperienced directors

ALX Oncology Holdings Inc., Annual General Meeting, Jun 14, 2022

ALX Oncology Appoints Itziar Canamasas, Ph.D., to Its Board of Directors

ALX Oncology Holdings Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Cancer

ALX Oncology Holdings Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Price target decreased to US$54.75

ALX Oncology Is Turning Into An Also-Ran In Anti-CD47

Chief Financial Officer exercised options to buy US$225k worth of stock.

Price target decreased to US$72.75

ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic Syndrome

ALX Oncology Stock: Attractive After Recent Data And Slump In Price

Chief Medical Officer & Director exercised options and sold US$487k worth of stock

Price target decreased to US$89.50

Chief Medical Officer & Director notifies of intention to sell stock

Alx Oncology Holdings Inc. Announces Initiation of Investigator-Sponsored Trial of Evorpacept (Alx148) in Patients with Indolent and Aggressive Non-Hodgkin Lymphoma

Chief Medical Officer & Director notifies of intention to sell stock

ALX Oncology Is The Next CD47 Biotech To Watch After Recent Acquisitions In This Space

Independent Director Graham Walmsley has left the company

Chief Financial Officer notifies of intention to sell stock